Anthony B Pinkerton

This inventor holds 44 USPTO granted patents and 13 published patent applications, plus 3 CIPO patents and 12 EPO patents, primarily in Apelin Receptor Agonists. Top assignees: Sanford Burnham Prebys Medical Discovery Institute, Sanford-Burnham Medical Research Institute, Daiichi Sankyo Company, Limited. Active years: 2012-2026.

USPTO Granted Patents = 44 (Patent Applications = 13)

% Patents Active = 84.1

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 12 (Patent Applications = 19)

Average Co-Inventor Count = 4.8

ph-index = 4

Forward Citations = 52(Granted Patents)

Location History:

San Diego, CA (US) (2012 - 2020)
La Jolla, CA (US) (2016 - 2024)
Rancho Santa Fe, CA (US) (2021 - 2024)

Company Filing History:

33 out of 99

Sanford Burnham Prebys Medical Discovery Institute

patents

6 out of 99

Sanford-Burnham Medical Research Institute

patents

5 out of 460

Daiichi Sankyo Company, Limited

patents

4. 2 out of 63

Ardea Biosciences, Inc

La Jolla Institute for Allergy and Immunology

University of Michigan

patents

9. 2 out of 602

Wayne State University

Mayo Foundation for Medical Education and Research

Selexagen Therapeutics, Inc.

patent

14. 1 out of 3,690

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

where one patent can have more than one assignee

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

Apelin Receptor

CHK1 Inhibitors

NAMPT Activators

Small Molecule Agonists

Protein Tyrosine Phosphatase

Fused Ring Compounds

Azole Derivatives

Biaryl Derivative

Neurotensin Receptor

Sulfonamide Compounds

Quinolinones

Pyridine Compounds

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12643910 - Substituted pyrazolo[3,4-b]pyridines as ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) modulators (2026-06-02),

2. 12527790 - Checkpoint kinase 1 (CHK1) inhibitors and uses thereof (2026-01-20),

3. 12319684 - Agonists of the apelin receptor and methods of use thereof (2025-06-03),

4. 12263159 - Fused ring compound having urea structure (2025-04-01),

5. 12071414 - Apelin receptor agonists and methods of use thereof (2024-08-27),

6. 12071413 - Azole derivatives as apelin receptor agonist (2024-08-27),

7. 12030896 - PIKfyve inhibitors (2024-07-09),

8. 12006321 - Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists (2024-06-11),

9. 11932600 - Biaryl derivative (2024-03-19),

10. 11918568 - Fused ring compound having urea structure (2024-03-05),

11. 11806337 - Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof (2023-11-07),

12. 11731986 - Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof (2023-08-22),

13. 11707462 - Checkpoint kinase 1 (CHK1) inhibitors and uses thereof (2023-07-25),

14. 11673873 - Apelin receptor agonists and methods of use thereof (2023-06-13),

15. 11452717 - Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof (2022-09-27),

Title: Innovations and Contributions of Anthony B. Pinkerton in Pharmaceutical Science

Introduction: Anthony B. Pinkerton, located in La Jolla, California, is a prolific inventor in the field of pharmaceutical sciences, holding an impressive total of 35 patents. His contributions focus on innovative compounds and methods that demonstrate significant potential in medical applications.

Latest Patents: Among his recent patents, one notable invention is a Biaryl derivative. This invention pertains to a compound or a pharmacologically acceptable salt noted for its superior tissue non-specific alkaline phosphatase inhibitory activity. The patent outlines a compound represented by a specific formula involving various chemical substitutions, indicating a complex structure aimed at therapeutic purposes. Another significant patent involves small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), including compositions and methods for leveraging these activators in medical treatments.

Career Highlights: Anthony B. Pinkerton has made a mark as a researcher with tenure at esteemed institutions such as the Sanford Burnham Prebys Medical Discovery Institute and the Sanford Burnham Medical Research Institute. His work has focused on cutting-edge research that intersects chemistry and biology, leading to innovative solutions in drug development.

Collaborations: Throughout his career, Pinkerton has collaborated with esteemed colleagues, including Michael P. Hedrick and Robert J. Ardecky. These partnerships have facilitated advancements in research, contributing to the development of novel therapeutics and enhancing the collective knowledge in the field.

Conclusion: Anthony B. Pinkerton's extensive array of patents and collaborative efforts underscore his commitment to advancing pharmaceutical science. His innovative inventions, particularly in the realm of novel compounds and therapeutic activators, highlight his significant role in improving medical outcomes and exemplify the spirit of innovation in the industry.